Upgrade to SI Premium - Free Trial

Valeant Pharmaceuticals (VRX) PT Lowered to $35 at Stifel, Keeps 'Buy' as Company Moves Beyond 'Stabilization Phase'

May 16, 2017 3:07 PM
Stifel lowered its price target on Valeant Pharmaceuticals (NYSE: VRX) to $35.00 (from $45.00) while maintaining a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst EPS Change Analyst PT Change

Next Articles